Literature DB >> 19909897

Current use for old antibacterial agents: polymyxins, rifamycins, and aminoglycosides.

Luke F Chen1, Donald Kaye.   

Abstract

This article reviews three classes of antibacterial agents that are uncommonly used in bacterial infections and therefore can be thought of as special-use agents. The polymyxins are reserved for gram-negative bacilli that are resistant to virtually all other classes of drugs. Rifampin is used therapeutically, occasionally as a companion drug in treatment of refractory gram-positive coccal infections, especially those involving foreign bodies. Rifaximin is a new rifamycin that is a strict enteric antibiotic approved for treatment of traveler's diarrhea and is showing promise as a possible agent for refractory Clostridium difficile infections. The aminoglycosides are used mainly as companion drugs for the treatment of resistant gram-negative bacillary infections and for gram-positive coccal endocarditis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19909897     DOI: 10.1016/j.idc.2009.06.004

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN: 0891-5520            Impact factor:   5.982


  15 in total

1.  Polymyxin use associated with respiratory arrest.

Authors:  Hannah Wunsch; Vivek K Moitra; Mona Patel; Amy L Dzierba
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 2.  Rifamycins, Alone and in Combination.

Authors:  David M Rothstein
Journal:  Cold Spring Harb Perspect Med       Date:  2016-07-01       Impact factor: 6.915

Review 3.  Antimicrobial Susceptibility Testing for Polymyxins: Challenges, Issues, and Recommendations.

Authors:  Fereshteh Ezadi; Abdollah Ardebili; Reza Mirnejad
Journal:  J Clin Microbiol       Date:  2019-03-28       Impact factor: 5.948

4.  Pharmacokinetics and efficacy of liposomal polymyxin B in a murine pneumonia model.

Authors:  Jie He; Kamilia Abdelraouf; Kimberly R Ledesma; Diana S-L Chow; Vincent H Tam
Journal:  Int J Antimicrob Agents       Date:  2013-08-22       Impact factor: 5.283

5.  A comparison of different antibiotic regimens for the treatment of infective endocarditis.

Authors:  Arturo J Martí-Carvajal; Mark Dayer; Lucieni O Conterno; Alejandro G Gonzalez Garay; Cristina Elena Martí-Amarista
Journal:  Cochrane Database Syst Rev       Date:  2020-05-14

6.  Gentamicin binds to the megalin receptor as a competitive inhibitor using the common ligand binding motif of complement type repeats: insight from the nmr structure of the 10th complement type repeat domain alone and in complex with gentamicin.

Authors:  Robert Dagil; Charlotte O'Shea; Anders Nykjær; Alexandre M J J Bonvin; Birthe B Kragelund
Journal:  J Biol Chem       Date:  2012-12-27       Impact factor: 5.157

7.  Genetic analysis of new 16S rRNA mutations conferring aminoglycoside resistance in Mycobacterium abscessus.

Authors:  Rachid Nessar; Jean Marc Reyrat; Alan Murray; Brigitte Gicquel
Journal:  J Antimicrob Chemother       Date:  2011-06-07       Impact factor: 5.790

Review 8.  New tides: using zebrafish to study renal regeneration.

Authors:  Kristen K McCampbell; Rebecca A Wingert
Journal:  Transl Res       Date:  2013-10-14       Impact factor: 7.012

9.  Colistin Therapy in a 23-Week Gestational-Age Neonate with Multidrug-Resistant Acinetobacter baumannii Pneumonia.

Authors:  Mirjana Lulic-Botica; Lilia Dejesus
Journal:  AJP Rep       Date:  2011-01-24

10.  Intermittent exposure to xenon protects against gentamicin-induced nephrotoxicity.

Authors:  Ping Jia; Jie Teng; Jianzhou Zou; Yi Fang; Suhua Jiang; Xiaofang Yu; Alison J Kriegel; Mingyu Liang; Xiaoqiang Ding
Journal:  PLoS One       Date:  2013-05-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.